Evidence map›Paper›PMID 33807260›Full record

ReviewBiomedicines2021

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy.

Alberto Cruz-Bermúdez, Raquel Laza-Briviesca, Marta Casarrubios, Belén Sierra-Rodero, Mariano Provencio

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Fuel for thought: targeting metabolism in lung cancer.Translational lung cancer research · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alberto Cruz-BermúdezMedical Oncology Department, Health Research Institute Puerta de Hierro-Segovia de Arana (IDIPHISA) & Puerta de Hierro Hospital, Manuel de Falla Street #1, 28222 Madrid, Spain.ORCID 0000-0001-5136-7011
Raquel Laza-BriviescaMedical Oncology Department, Health Research Institute Puerta de Hierro-Segovia de Arana (IDIPHISA) & Puerta de Hierro Hospital, Manuel de Falla Street #1, 28222 Madrid, Spain.
Marta CasarrubiosMedical Oncology Department, Health Research Institute Puerta de Hierro-Segovia de Arana (IDIPHISA) & Puerta de Hierro Hospital, Manuel de Falla Street #1, 28222 Madrid, Spain.
Belén Sierra-RoderoMedical Oncology Department, Health Research Institute Puerta de Hierro-Segovia de Arana (IDIPHISA) & Puerta de Hierro Hospital, Manuel de Falla Street #1, 28222 Madrid, Spain.
Mariano ProvencioMedical Oncology Department, Health Research Institute Puerta de Hierro-Segovia de Arana (IDIPHISA) & Puerta de Hierro Hospital, Manuel de Falla Street #1, 28222 Madrid, Spain.ORCID 0000-0001-6315-7919
Hospital Universitario Puerta de Hierro Majadahonda · ES

Funding

European Social Fund PEJ16/MED/AI-1972European Social Fund PEJD-2018-PRE/SAL-8641European Social Fund PEJD-2019-PRE/BMD-17006Horizon 2020 Framework Programme CLARIFY 875160Instituto de Salud Carlos III PI19/01652Instituto de Salud Carlos III "Sara Borrell" contract CD19/00170.Ministerio de Ciencia, Innovación y Universidades RTC2017-6502-1 INmunoSIGHT
6 · The paper itself

Abstract

The tumor microenvironment exhibits altered metabolic properties as a consequence of the needs of tumor cells, the natural selection of the most adapted clones, and the selfish relationship with other cell types. Beyond its role in supporting uncontrolled tumor growth, through energy and building materials obtention, metabolism is a key element controlling tumor immune evasion. Immunotherapy has revolutionized the treatment of cancer, being the first line of treatment for multiple types of malignancies. However, many patients either do not benefit from immunotherapy or eventually relapse. In this review we overview the immunoediting process with a focus on the metabolism-related elements that are responsible for increased immune evasion, either through reduced immunogenicity or increased resistance of tumor cells to the apoptotic action of immune cells. Finally, we describe the main molecules to modulate these immune evasion processes through the control of the metabolic microenvironment as well as their clinical developmental status.

Indexed as

immune evasionimmunotherapymetabolismnew drugs

Identifiers

PMID33807260
PMCPMC8067102
OpenAlexW3144494241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.